Screener
Jazz Pharmaceuticals JAZZ Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued liabilities | (7.9) | 181.0 |
| Income taxes payable | 37.4 | 13.0 |
| Other liabilities | 12.2 | 2.9 |
| Net cash provided by operating activities | 408.2 | 429.8 |
| Investing activities | ||
| Proceeds from maturity of investments | 520.0 | 310.0 |
| Proceeds from sale of priority review voucher | 200.0 | — |
| Payments related to sale of priority review voucher | (77.2) | — |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's operating cash flow?
- Jazz Pharmaceuticals (JAZZ) reported operating cash flow of $408.2M in Q1 2026.
- How has Jazz Pharmaceuticals's operating cash flow changed year-over-year?
- Jazz Pharmaceuticals's operating cash flow decreased by 5.0% year-over-year, from $429.8M to $408.2M.
- What is the long-term trend for Jazz Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's operating cash flow has grown at a 14.9% compound annual growth rate (CAGR), from $778.51M to $1.36B.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Jazz Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude